Novo Nordisk remains a Buy due to its strong long-term fundamentals and leadership in obesity treatment, particularly with its Wegovy pill. Although the company faces short-term issues like declining gross margins, high capital expenditures, and a failed drug trial, its operating margins and capital management are solid. Management has improved its 2026 guidance, now expecting adjusted sales and operating profit to decline by up to 6%, better than previous forecasts. The stock trades at a valuation below its 10-year average, with confidence in a return to double-digit growth annually.
Crude oil prices surged above $100 per barrel after drone attacks forced Saudi Arabia to shut its critical East-West pipeline, which carries about 4 million barrels per day to the Red Sea port of Yanbu. This pipeline outage threatens up to 4% of the ...
Morgan Stanley downgraded Novo Nordisk to "Underweight" with a price target of $40, implying a 9.11% downside from its recent price of $44.01. The downgrade reflects concerns over a projected 21.57% drop in earnings per share to $0.80 and a 2.35% rev...
